

# Second NYC Symposium on RAS Biology and Therapies

October 6, 2026 | 8:30 am-6:30 pm

Davis Auditorium

The Leon and Norma Hess Center for Science and Medicine, 1470 Madison Ave, New York, NY

## AGENDA

**8:30 AM | BREAKFAST AND REGISTRATION**

**9:00 AM OPENING REMARKS**

**Ramon Parsons** (Director, Mount Sinai Tisch Cancer Center, Icahn School of Medicine at Mount Sinai)  
&  
**Poulikos I. Poulikakos** (Co-Leader, Cancer Mechanisms Program, Mount Sinai Tisch Cancer Center)

**9:10 AM    SESSION 1: RAS Signaling Networks and Mechanisms**

**Pau Castel** (New York University)  
*"Regulation of RAS GTPases by proteolysis"*

**Mark Philips** (New York University)  
*"KRAS4A Directly Regulates Methionine Synthase"*

**Benjamin Neel** (New York University)  
*"How SHP2 activates RAS"*

**Short Talk**

**Kamini Singh** (Montefiore Einstein Comprehensive Cancer Center)  
*"Targeting mRNA Translation to Drive Immunity in Mutant KRAS-driven Cancer"*

**10:20 AM | BREAK**

**10:30 AM    SESSION 2: RAS-Directed Therapies**

**Piro Lito** (Memorial Sloan Kettering Cancer Center)  
*"Targeting RAS: From Biochemical Mechanisms to Tumor Adaptation in Patients"*


**Short Talk**

**Rajwanth Veluswamy** (New York University)  
*"The NYU KRAS Excellence Initiative"*

## KEYNOTE SPEAKER

**Frank McCormick (UCSF)**  
*"RAS signaling in normal cells and in cancer"*

**12:00 PM | LUNCH**



# Second NYC Symposium on RAS Biology and Therapies

October 6, 2026 | 8:30 am-6:30 pm

Davis Auditorium

The Leon and Norma Hess Center for Science and Medicine, 1470 Madison Ave, New York, NY

## AGENDA

### 1:00 PM SESSION 3: RAS Biology and Disease Modeling

#### Short Talk

**Vinh Ton** (New York University)

*"Isoform-selective targeting of the RAF RAS-binding domain with monobodies to block oncogenic RAS signaling"*

**Kenneth Olive** (Columbia University)

*"Chemotherapy potentiates RAS inhibition through induced plasticity"*

**Eirini Papapetrou** (Icahn School of Medicine at Mount Sinai)

*"RAS-mutant leukemia stem cells promote therapy resistance through cell-autonomous and non-cell-autonomous mechanisms"*

**Lukas Dow** (Weill Cornell Medicine)

*"Genetic and non-genetic drivers of resistance to KRAS inhibition"*

#### Short Talk

**Leah Kravets** (Albert Einstein College of Medicine)

*"KRAS G12D Blocks Erythroid Differentiation and Promotes Inflammatory Pathways at the Single Cell Level in Myeloid Malignancies"*

### 2:30 PM | BREAK

### 2:40 PM SESSION 4: Mechanisms of Tumor Response and Resistance

**Neal Rosen** (Memorial Sloan Kettering Cancer Center)

*"Using heterogeneity of response to RAS inhibitors as a guide to combination therapy"*

**Rona Yaeger** (Memorial Sloan Kettering Cancer Center)

*"Challenges and Progress in Targeting RAS in Colorectal Cancers"*

#### Short Talks


**Hee-Won Yang** (Columbia University)

*"NRAS-RTK AND-gate enables cell-cycle escape from RAS inhibition"*

**Sicong Ma** (New York University)

*"Exploiting the Plasticity/Persistence Nexus to Improve Targeted Therapy of Cancer"*

### 3:35 PM | BREAK



# Second NYC Symposium on RAS Biology and Therapies

October 6, 2026 | 8:30 am-6:30 pm

Davis Auditorium

The Leon and Norma Hess Center for Science and Medicine, 1470 Madison Ave, New York, NY

## AGENDA

### 3:45 PM SESSION 5: Novel Pharmacological Approaches

**Arvin Dar** (Memorial Sloan Kettering Cancer Center)

*"Modulation of Cancer Specific Interactomes via Chemical Switches and Molecular Glues"*

**Evripidis Gavathiotis** (Albert Einstein College of Medicine)

*"Exploiting RAF Conformational Dynamics for Durable MAPK Pathway Inhibition"*

**Poulikos I. Poulikakos** (Icahn School of Medicine at Mount Sinai)

*"Targeting RAS-Mutant Cancers with Conformation-Selective Inhibitors and Molecular Glues"*

#### Short Talks

**Tomas Frankovich** (Memorial Sloan Kettering Cancer Center)

*"A covalent KRAS G12C tracer to monitor  $k_{inact}$  and  $K_i$  in live cells"*

**Natalie Thielen** (Albert Einstein College of Medicine)

*"High-Throughput Screening Identifies NT-1 as a Dual JAK3/EGFR Inhibitor that Overcomes KRAS Inhibitor Resistance in Colorectal Cancer"*

### 4:50 PM | CLOSING REMARKS

### 5:00 PM | ADJOURN

### 5:00 - 6:30 PM | POSTERS AND RECEPTION

# Second NYC Symposium on RAS Biology and Therapies

October 6, 2026 | 8:30 am-6:30 pm  
Davis Auditorium

The Leon and Norma Hess Center for Science and Medicine, 1470 Madison Ave, New York, NY

## POSTERS

| Poster Number | Name                 | Poster Title                                                                                                                                                           |
|---------------|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1             | Yashika Agrawal      | <i>SHP2 Signals to RAS By Acting as a PTP Domain-Dependent, PTP Activity-Independent Scaffold</i>                                                                      |
| 2             | Tomas Frankovich     | <i>A covalent KRAS G12C tracer to monitor <math>k_{inact}</math> and <math>K_i</math> in live cells</i>                                                                |
| 3             | Bijaya Gaire         | <i>Spatial modulation of RAF by RAF/MEK glue enables full-dose combination with pan-RAF inhibitor and potent RAS-mutant tumor-selective MAPK and growth inhibition</i> |
| 4             | Ziyue Kou            | <i>KRASG12 tumor-selective RAS suppression by RAS-ON and KRAS-OFF blockade</i>                                                                                         |
| 5             | Leah Kravets         | <i>KRAS G12D Blocks Erythroid Differentiation and Promotes Inflammatory Pathways at the Single Cell Level in Myeloid Malignancies</i>                                  |
| 6             | Sicong Ma            | <i>Exploiting the Plasticity/Persistence Nexus to Improve Targeted Therapy of Cancer</i>                                                                               |
| 7             | Evangelia Matenoglou | <i>Hinge-targeting RAF inhibitors with prolonged residence time for durable suppression of MAPK signaling</i>                                                          |
| 8             | Hiral Mistry         | <i>Targeting ARAF-Bound MEK with a Covalent Super Glue to Antagonize Oncogenic RAS</i>                                                                                 |
| 9             | Nazifa Salsabeel     | <i>Deciphering the Molecular Crosstalk Between the PRC2 complex and Ras signaling in Merkel Cell Carcinoma</i>                                                         |
| 10            | Kamini Singh         | <i>Targeting Mutant KRAS-driven mRNA Translation to Drive Cancer Immunity</i>                                                                                          |
| 11            | Rajesh Kumar Soni    | <i>Deep Secretome Profiling Reveals KRAS Mutation-Associated Secreted Proteins in Pancreatic Cancer Using Nanoparticle-Enabled Proteomics</i>                          |
| 12            | Natalie Thielen      | <i>High-Throughput Screening Identifies NT-1 as a Dual JAK3/EGFR Inhibitor that Overcomes KRAS Inhibitor Resistance in Colorectal Cancer</i>                           |
| 13            | Vinh Ton             | <i>Isoform-selective targeting of the RAF RAS-binding domain with monobodies to block oncogenic RAS signaling</i>                                                      |
| 14            | Alec Vaughan         | <i>KEAP1-NRF2 mediated resistance to KRAS inhibition is overcome by targeting glutamine dependency in pancreatic and lung cancer</i>                                   |



# Second NYC Symposium on RAS Biology and Therapies

October 6, 2026 | 8:30 am-6:30 pm

Davis Auditorium

The Leon and Norma Hess Center for Science and Medicine, 1470 Madison Ave, New York, NY

## FACULTY SPEAKERS

### **PAU CASTEL, PhD**

Assistant Professor  
Department of Biochemistry and Molecular Pharmacology  
NYU School of Medicine

### **ARVIN DAR, PhD**

Member, Professor  
Chemical Biology Program  
Sloan Kettering Institute  
Memorial Sloan Kettering Cancer Center

### **LUKE DOW, PhD**

Professor  
Weill Cornell Medicine

### **EVRIPIDIS GAVATHIOTIS, PhD**

Professor of Biochemistry, Medicine, and Oncology  
Co-Leader, Cancer Therapeutics Program  
Albert Einstein College of Medicine  
Montefiore Einstein Comprehensive Cancer Center

### **PIRO LITO, MD, PhD**

Enid A. Haupt Chair in Therapeutic Research  
Memorial Sloan Kettering Cancer Center

### **FRANK MCCORMICK, PhD, FRS**

David A. Wood Distinguished Professor of Tumor Biology & Cancer Research  
UCSF Helen Diller Family Comprehensive Cancer Center

### **BENJAMIN NEEL, MD, PhD**

Professor of Medicine  
NYU Grossman School of Medicine

### **KENNETH OLIVE, PhD**

Professor of Medicine  
Assistant Dean of PhD Curricula  
Columbia University Vagelos College of Medicine

### **EIRINI PAPAPETROU, MD, PhD**

Professor, Department of Oncological Sciences  
Director, Center for Advancement of Blood Cancer Therapies  
Icahn School of Medicine at Mount Sinai

### **MARK PHILIPS, MD**

NYU Grossman School of Medicine

### **POULIKOS I. POULIKAKOS, PhD**

Professor, Department of Oncological Sciences  
Co-Leader, Cancer Mechanisms Program  
Mount Sinai Tisch Cancer Center  
Icahn School of Medicine at Mount Sinai

### **NEAL ROSEN, MD, PhD**

Emeritus Professor  
Molecular Pharmacology  
Memorial Sloan Kettering Cancer Center

### **KAMINI SINGH, PhD**

Assistant Professor  
Montefiore Einstein Comprehensive Cancer Center

### **RAJWANTH VELUSWAMY, MD, MSCR**

Associate Professor  
Co-Director of KRAS Excellence Initiative at Perlmutter Cancer Center  
NYU Langone Health

### **RONA YAEGER, MD**

Attending Physician  
Memorial Sloan Kettering Cancer Center

### **HEE WON YANG, PhD**

Assistant Professor  
Columbia University

## SYMPOSIUM ORGANIZER (*on behalf of the Mount Sinai Tisch Cancer Center*)

### **POULIKOS I. POULIKAKOS, PhD**

Professor, Department of Oncological Sciences  
Co-Leader, Cancer Mechanisms Program  
Mount Sinai Tisch Cancer Center  
Icahn School of Medicine at Mount Sinai

